Piramal Pharma reported operating revenue of ₹8,869 crore in fiscal 2026, according to its annual report released on July 8, as the Indian drugmaker leaned on its contract manufacturing arm and regulated markets for growth.
The company's contract development and manufacturing unit, Piramal Pharma Solutions, contributed 55% of total revenue while serving more than 500 clients. Roughly two-thirds of sales came from regulated markets. Piramal Critical Care retained its top position in the U.S. sevoflurane market and completed the acquisition of Kenalog, while the consumer healthcare division launched 31 new products.
The company, which operates 17 manufacturing sites globally, committed $90 million to expand sterile injectables and payload linker capacity. It also passed 38 regulatory inspections, including three by the U.S. FDA, with no official action indicated.